Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Exclusion Criteria

• •Clinically evident congestive heart failure \> NYHA Class 2 (See Appendix 10.4)
• •Serious cardiac arrhythmias (for example requiring anti-arrhythmics)
• •Myocardial infarction or symptomatic coronary artery disease (severe or unstable angina) within 6 months prior to screening
• •Active clinically serious infections (\> Grade 2 NCI-CTC)
• •Patients with history of brain metastases are eligible as long as the metastasis has been treated with either stereotactic or whole brain radiation, stereotactic gamma-knife radiosurgery or neurosurgery, patient does not require ongoing treatment with dexamethasone, the patient is not on anticoagulant therapy and whose radiographic imaging is stable ≥ 4 weeks from start of treatment. Time from brain metastasis treatment to first study treatment must meet the following criteria:
• •* Stereotactic or whole brain radiation, stereotactic gamma-knife radiosurgery ≥ 4 weeks from first study treatment
• •* Neurosurgery ≥ 24 weeks from first study treatment
• •* Brain biopsy ≥ 12 weeks from first study treatment
• •History of organ allograft
• •Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed
• •Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management
• •Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
• •Peripheral neuropathy \> or equal to Grade 2
• •Thrombotic or embolic events (such as transient ischemic attacks, myocardial infarction, pulmonary embolus), within 6 months prior to Screening
• •Pulmonary hemorrhage/bleeding event \> CTCAE Grade 2 within 4 weeks of first study treatment
• •Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first study treatment
• •Evidence or history of bleeding diathesis or coagulopathy
• •Serious, non-healing wound, ulcer, or bone fracture
• •Patients undergoing renal dialysis
• •Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study treatment
• •Previous cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors \[Ta and Tis\] or any cancer curatively treated \> 3 years prior to first study treatment
• •Non small cell lung cancer
• •Ongoing substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
• •Pregnant or breast-feeding patients.
• •Known or suspected allergy to the investigational agent or any agent given in association with this trial
• •Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
• •Any condition that impairs patient's ability to swallow whole pills
• •Any malabsorption condition